July 6, 2020
Heta compiler has been published on GitHub as an OpenSource
(Moscow-06.07.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents Heta compiler which is a tool for the development of Quantitative Systems Pharmacology and Systems Biology platforms. Particularly, it allows combining modules written in different formats like: Heta language code, Excel sheets, JSON, YAML formatted structures, SBML and transforming them into the dynamic models of different formats.
It should be outlined, that Quantitative Systems Pharmacology (QSP) is a discipline that uses mathematical computer models to characterize biological systems, to determine the optimal doses, target groups of patients and substances effect on the human body. QSP typically functions through mechanism-based dynamical models described by ODE systems. Therefore, the modeling systems may include hundreds or thousands of components and are developed by a research group involving people with different expertise. Evgeny Metelkin, Head of InSysBio product development, highlights: “Heta compiler can be used as the framework for a QSP modeling project of any size and complexity. It can be easily integrated with existed infrastructure, workflows or used as a part of the CI/CD strategy”.
Actually, Heta compiler is a tool that allows to perform a number of functions, namely:
Heta compiler is developed as Free Open Source project published on GitHub. The actual version of Heta compiler is 0.5.3, which supports Heta language of version 0.3.1.
Heta compiler is written in JаvaScript/Node language and is distributed as a npm package. This software can work in command line tool mode or may be used as a package for browser or server-side tools and applications.
Heta compiler has already supported the fulfillment of a number of InSysBio projects, namely:
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | June 2020 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
1.
02 Jun 2020 13:24
InSysBio to announce the launch of QSP model of COVID-19
The new open source project to be developed and updated Online
InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the launch of its fundamentally new project in response to the ongoing global threat, the open source QSP model of COVID-19. In accordance with its mission, which is to assist pharmaceutical industry to speed up the delivery of the cure to patients, InSysBio team could not stay aside. Thus, the aim of the new project is to develop QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
|
3
|
4
|
5
1.
05 Jun 2020 15:04
InSysBio to present IRT Navigator 3
InSysBio presents IRT Navigator 3 which is an application software providing intuitive interface to work with the Immune Response Template Database in accordance with the user’s needs. It supplies the navigation within the schemes and components and efficient development of QSP models based on IRT Database.
|
6
|
7
|
|
8
1.
08 Jun 2020 15:30
InSysBio to perform the first step in development of COVID-19 QSP model
InSysBio has performed the first step in the direction of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
|
9
|
10
|
11
|
12
1.
12 Jun 2020 16:45
InSysBio to release the new version of Cytocon DB 1.1.6.4
We are glad to announce the release of the new version of Cytocon DB 1.1.6.4. The DB was significantly extended with new data due to well-coordinated workflow of Cytocon DB team and its new members. Namely, 54 diseases, 24 tissues, 42 molecules, 24 cells and 3701 concentrations were introduced.
|
13
|
14
|
|
15
|
16
|
17
1.
17 Jun 2020 15:48
InSysBio to welcome its new team member Dr. Neil Benson
InSysBio announces the appointment of Dr. Neil Benson as Principal Consultant in area of business development
(Edinburgh-Moscow-16.06.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, is proud to announce its new team member Dr. Neil Benson! Dr. Benson has joined InSysBio as Principal Consultant in area of business development of both INSYSBIO LLC and INSYSBIO UK LIMITED. In his capacity as Principal Consultant to InSysBio, he will support further development of the outstanding IO and AD QSP offering of the company.
|
18
|
19
|
20
|
21
|
|
22
1.
22 Jun 2020 17:04
InSysBio team posters to be presented at AACR Virtual Annual Meeting II
AACR Virtual Annual Meeting II has begun! American Association for Cancer Research Annual Meeting is held virtually this year on June 22-24 due to COVID-19 spread. Today InSysBio team's posters were published on AACR website
|
23
|
24
|
25
|
26
|
27
|
28
|
|
29
|
30
1.
30 Jun 2020 15:45
InSysBio to present COVID-19 QSP model further development
InSysBio continues to move forward in COVID-19 QSP model development. Its aim is to describe virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
| |||||
Thank you for your message! We will get back to you shortly.
